Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Second-generation h1 antihistamines
11 evidence topics · 6 sources
First-line standard-dose second-generation H1-antihistamine: 2026 international guideline
“We recommend a 2nd generation H1‐antihistamine as first‐line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most, but not all 2nd generation H1‐antihistamines have been tested specifically in urticaria, and evidence supports the use of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend the use of a standard‐dosed modern 2nd generation H1‐antihistamines as the first‐line symptomatic treatment for urticaria. However, no recommendation can be made on which to choose because, to date, well‐designed clinical trials directly comparing the efficacy and safety of all modern 2nd generation H1‐antihistamines in urticaria are largely lacking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest 2nd generation H1‐antihistamines to be taken regularly for the treatment of patients with chronic spontaneous urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Updosing up to four-fold as second-line treatment: 2026 international guideline
“We recommend updosing of a 2nd generation H1‐antihistamine up to 4‐fold in patients with chronic urticaria unresponsive to a standard‐dosed 2nd generation H1‐antihistamines as second‐line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against using higher than 4‐fold standard dosed H1‐antihistamines in chronic urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients need to be informed that 2nd generation H1‐antihistamine updosing is off‐label and higher than fourfold is not recommended as it has not been tested.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For updosing, also the time of onset needs to be considered, for example, for treatment with an antihistamine, further improvement cannot be expected after 1–2 weeks of treatment as receptor saturation is complete after 1 week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-generation H1-antihistamines and combinations of antihistamines: 2026 international guideline
“The older 1st generation H1‐antihistamines have pronounced anticholinergic and sedative effects and many interactions with alcohol and other drugs such as analgesics, hypnotics, sedatives, and mood elevating drugs, have been described.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we recommend against their use for the routine management of CU as first‐line agents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against using different H1‐antihistamines at the same time (against an updosing of a single H1‐antihistamine if not legally restricted in country)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukotriene receptor antagonists as add-on therapy: 2026 international guideline
“In general, the level of evidence for the efficacy of leukotriene receptor antagonists in urticaria is low, but the most so far for montelukast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A recent, systematic review and meta‐analysis found that adding leukotriene receptor antagonists to H1 antihistamines provides modest reductions in urticaria activity without significantly increasing overall adverse events, though the risk of neuropsychiatric effects remains uncertain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Draft 2026 AAAAI/ACAAI Joint Task Force guideline: review invitation and scope
Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update
Montelukast and H2 blocker adjuncts to a second-generation antihistamine: urticaria activity
Sedation by agent and dose
Implications for guidelines and payers of diminishing benefit beyond a standard dose
Response to updosing among standard-dose nonresponders: systematic review and meta-analysis
“The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled disease at Month 24 on non-sedating and updosed antihistamines: AWARE real-world study, sponsored by the omalizumab manufacturer
“AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote